´ÙÀ½°ú °°ÀÌ ÃÊ·Ï Á¢¼ö ¿Ï·áµÇ¾ú½À´Ï´Ù. Abstract Submission Site: Symposium on Advanced Wound Care-WHS Spring 2019
You can access your Abstract at any time Abstract Type: Poster if not accepted as an Oral Presentation Abstract Status: Complete Abstract Title: Prospective Single-blind Multi-Center Randomized Controlled Trial Comparing Allogenic Adipose Derived Stem Cell Hydrogel Versus Standard Wound Care To Evaluate Safety/Efficacy in Management of Non Healing Diabetic Foot Ulcers Author(s) 1.David Armstrong, MD, DPM, PhD (Role: Author) 2.Seung-Kyu Han, MD, PhD (Role: Author) 3.Hyun-Suk Suh, MD, PhD (Role: Author) 4.Ki-Won Young, MD, PhD (Role: Author) 5.Charles M. ZELEN, DPM (Role:Author ) Abstract Submission Title Prospective, Single-blind, Multi-Center Randomized Controlled Trial Comparing Allogenic Adipose Derived Stem Cell - Hydrogel Versus Standard Wound Care To Evaluate Safety/ Efficacy in Management of Non Healing Diabetic Foot Ulcers Track Clinical Research Has this abstract been previously presented? •No Abstract Mesenchymal stem cells (MSCs) hold great promise for treating diabetic wounds. Recent advancements in technology have led to the introduction of adipose derived allogeneic stem cells into a hydrogel sheet creating a unique medium for application on the non-healing diabetic foot wound. The purpose of this phase II clinical trial was to report the efficacy and safety of allogeneic stem cells(ASC) for treating diabetic foot ulcers. Fifty-nine patients with non healing diabetic foot ulcers, Wagner one and two, were randomized to receive either weekly application of ASC hydrogel sheets along with standard wound care(n = 30) or control group, treated with polyurethane film, also with standard wound care(n = 29). These wounds were evaluated weekly for up to 12 weeks. The primary endpoint was complete wound closure at 12 weeks. Primary: Allogenic stem cell sated onto a hydrogel sheet Poster abstract sponsor Anterogen Seoul Korea
|